Xuehao Wang, MD

Academician of the Chinese Academy of Engineering, director of the Institute of Liver Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, China

Dr. Prof. Wang received his medical master degree from Nanjing Medical University in 1982. He was trained on liver surgery in the University of Pittsburgh-Pittsburgh between September 1983 and October 1985.

Dr. Prof. Wang is an Academician of the Chinese Academy of Engineering, Professor (grade A), tutor of doctoral candidates, chief physician. Currently he is the director of the Institute of Liver Surgery, the First Affiliated Hospital of Nanjing Medical University, director of the clinical key discipline of organ transplantation of the National Health and Family Planning Commission (NHFPC), director of key laboratory, member of the human organ transplantation expert group, chief of the Group of Transplant Immunology, Chinese Medical Association, director of Liver Transplantation Center of Jiangsu Province, and vice president of Medical Association of Jiangsu Province. He is the member of the editorial boards of top journals including HBPT INT, WJG, Chinese Journal of Organ Transplantation, Chinese Journal of Digestive Surgery, and Chinese Journal of Bases and Clinics in General Surgery.

Dr. Wang is a pioneer in living donor liver transplantation (LDLT) in mainland China and also one of the few scholars who adopted LDLT in clinical practices worldwide. In mainland China, Dr. Wang for the first time established a standard technical system for LDLT and promoted this technique nationwide. His unremitting efforts paved the way for the wide adoption of LDLT.   His innovative insights about the basics and clinical application of living related liver donor transplantation for Wilson's disease bring new light to the surgical treatment of this disease. Early in June 1986, he was the first Chinese author that reported the role of hepatic artery angiography with iodinated oil in the diagnosis of liver cancer, which paved the way for the modern interventional treatment for liver cancer in China. In November 2012, under his leadership and supervision, the resected liever specimens carrying hemangioma, which had been discarded in conventional practices, were transplanted into liver cancer patients, and the outcomes were quite good. This attempt provided new insight for the maximal use of marginal liver in liver transplantation. In recent years, he has carried out or completed 4 research projects supported by the National Natural Science Fund and/or National "Eighth Five-year" Science and Technology Research Program, over 30 projects supported by provincial or ministerial research funds, and over 30 projects supported by the provincial health authorities or the Nanjing Medical University. The overall grants exceed 20 million RMB yuan. As the principal investigator, he was the winner of one National Scientific and Technological progress Award (second prize), one Jiangsu Provincial Science and Technology Progress Award (first prize), and six provincial or ministerial research awards (second prizes). His honorable titles included "National Health System Excellent Worker", "Norman Bethune-style Medical Staff", "Advanced Worker", and "Nanjing 's City Hero in Science and Technology". He was the winner of the "Award for Outstanding Contributions in Medicine" and the "Jiangsu Province Outstanding Medical Award". In 2015, he won the noble title of "National Advanced Worker". He has obtained 3 invention patents. He has published over 400 scientific articles, among which 85 were published in SCI-indexed journals (as the first author or corresponding author). He is the editor, deputy editor, or contributor of 20 monographs. Among his students, 1 has been titled as the Cheung Kong Scholar, 1 was the winner of the National Outstanding Youth Fund, 1 was listed in the Jiangsu Province Leading Talents and 5 as Key Talents, 10 were listed in the Jiangsu Province 333 Engineering Talents, and 11 were listed as the Peak Talents in Six Key Disciplines.

Terms of Appointment: Aug 2019 - Jul 2024